Capricor Therapeutics (NASDAQ:CAPR) Stock Rating Reaffirmed by Cantor Fitzgerald

Capricor Therapeutics (NASDAQ:CAPR)‘s stock had its “overweight” rating restated by equities research analysts at Cantor Fitzgerald in a report issued on Friday, Benzinga reports. They currently have a $8.00 target price on the biotechnology company’s stock. Cantor Fitzgerald’s price target points to a potential upside of 58.42% from the stock’s previous close.

CAPR has been the topic of a number of other research reports. Oppenheimer upped their price objective on Capricor Therapeutics from $14.00 to $15.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 17th. HC Wainwright reiterated a “buy” rating and issued a $40.00 price target on shares of Capricor Therapeutics in a research note on Tuesday, September 17th. Finally, Maxim Group restated a “buy” rating and set a $12.00 price objective on shares of Capricor Therapeutics in a research note on Tuesday, September 17th. One analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $20.00.

Capricor Therapeutics Trading Up 1.2 %

Capricor Therapeutics stock opened at $5.05 on Friday. Capricor Therapeutics has a 1-year low of $2.68 and a 1-year high of $7.28. The company has a fifty day simple moving average of $4.37 and a 200 day simple moving average of $5.18. The company has a market cap of $161.49 million, a P/E ratio of -5.80 and a beta of 3.92.

Capricor Therapeutics (NASDAQ:CAPR) last announced its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.03). Capricor Therapeutics had a negative net margin of 102.93% and a negative return on equity of 220.27%. The company had revenue of $3.97 million during the quarter, compared to the consensus estimate of $4.51 million. On average, equities research analysts forecast that Capricor Therapeutics will post -1.24 EPS for the current year.

Hedge Funds Weigh In On Capricor Therapeutics

Large investors have recently modified their holdings of the stock. Jump Financial LLC acquired a new position in Capricor Therapeutics in the 4th quarter valued at about $258,000. BNP Paribas Financial Markets bought a new position in shares of Capricor Therapeutics during the first quarter worth approximately $40,000. Vanguard Group Inc. increased its stake in shares of Capricor Therapeutics by 17.2% during the first quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company’s stock worth $9,274,000 after purchasing an additional 200,499 shares during the period. Bank of New York Mellon Corp boosted its stake in Capricor Therapeutics by 12.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock valued at $381,000 after purchasing an additional 9,040 shares during the period. Finally, Rhumbline Advisers acquired a new position in Capricor Therapeutics in the 2nd quarter valued at $147,000. 21.68% of the stock is owned by institutional investors.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.